Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma : Theranostic Insights.

Clinical nuclear medicine - 1 Jun 2026

Beyler Özlem, Kömek Halil, Güzel Yunus, Demir Cengiz, Can Canan

Abstract excerpt

68 Ga-CXCR4 PET/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone 18 F-FDG PET/CT. Compared with 18 F-FDG PET/CT, 68 Ga-CXCR4 PET/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fluorodeoxyglucose F18
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CXCR4 gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Positron Emission Tomography Computed Tomography

Share to Precision Medicine

Share to Receptors, CXCR4

Source

Open in PubMed Open full text

Identifiers

PMID: 40644591
DOI: 10.1097/RLU.0000000000006052
PMCID: PMC13132033

Genes

CXCR4
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma : Theranostic Insights.PMID 40644591Read ↗

CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia.Semantic proximity Read ↗

68Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary resultsSemantic proximity Read ↗

The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemiaSemantic proximity Read ↗

68Ga-Pentixafor PET/CT imaging for in-vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: Correlation with quantitative receptors’ density by immunochemistry techniquesSemantic proximity Read ↗

Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [64Cu]AMD3100 Positron Emission TomographySemantic proximity Read ↗

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.Semantic proximity Read ↗

Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoidesSemantic proximity Read ↗

A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.